Clearside Biomedical Is Maintained at Buy by Chardan Capital
JonesTrading Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position
Oppenheimer Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Needham Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Needham Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target